Anixa Biosciences (NASDAQ:ANIX) Given “Buy” Rating at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 118.75% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, January 22nd. Maxim Group started coverage on Anixa Biosciences in a report on Friday. They set a “buy” rating and a $10.00 target price for the company.

Anixa Biosciences Price Performance

NASDAQ ANIX opened at $3.20 on Tuesday. The company has a 50-day moving average of $2.91 and a 200-day moving average of $3.00. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20. The company has a market cap of $103.03 million, a P/E ratio of -8.21 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). As a group, equities research analysts anticipate that Anixa Biosciences will post -0.41 EPS for the current year.

Insiders Place Their Bets

In other Anixa Biosciences news, CEO Amit Kumar bought 43,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the firm’s stock in a transaction dated Friday, January 17th. The shares were bought at an average cost of $2.57 per share, with a total value of $25,700.00. Following the transaction, the director now directly owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 75,289 shares of company stock worth $177,021 in the last quarter. 25.30% of the stock is owned by corporate insiders.

Institutional Trading of Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of Anixa Biosciences in the 4th quarter worth approximately $26,000. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences during the 3rd quarter valued at approximately $34,000. Renaissance Technologies LLC lifted its stake in Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after purchasing an additional 3,900 shares during the last quarter. Prosperity Wealth Management Inc. acquired a new position in Anixa Biosciences in the fourth quarter worth $54,000. Finally, Jane Street Group LLC bought a new stake in Anixa Biosciences during the fourth quarter valued at $67,000. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.